Compare Entegris Inc (ENTG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Incyte Corporation — how do they compare? Entegris Inc trades at $165.79 (market cap $24.78B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Entegris Inc and Incyte Corporation are close in size by market cap, and Entegris Inc pays a 0.25% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Incyte Corporation for 33 Days on average.
| ENTG | INCY | |
|---|---|---|
Market Cap | $24.78B | $22.85B |
Volume | 2,648,320 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $184.00 | $129.93 |
52-Week Low | $68.80 | $83.80 |
Typical Hold Time | 41 Days | 33 Days |
Enterprise Value | $27.99B | $18.35B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $165.79, down 0.32% on the day, with strong technical momentum as the stock approaches resistance at $166. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.93 beating expectations by 13%, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B with improving net margins of 9.18%. Recent news highlights institutional accumulation and patent defense successes.
Outlook remains positive with 70% analyst buy ratings and $182.43 consensus target suggesting 10% upside. Key catalysts include Q3 earnings on October 29 and Investor Day on November 9. Risks include elevated valuation multiples (P/E 81.1) and semiconductor cycle sensitivity. The stock offers growth exposure to advanced semiconductor materials with institutional confidence.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
